Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT06883305 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06883305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06883305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
March 18, 2025
Completion date
June 5, 2029
Enrollment
990 (estimated)
Sites
305

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)